All Infectious disease articles
-
NewsExperimental HIV vaccine generates broadly neutralising antibodies in primates
A collaborative research team from LJI, Scripps Research and IAVI has developed an experimental HIV vaccine that successfully generated broadly neutralising antibodies in rhesus macaques, marking a pivotal advance in the 14-year effort to design an effective HIV vaccine.
-
NewsAI and lab techniques accelerate tuberculosis drug discovery
Researchers at UMass Amherst have combined high-throughput laboratory screening with an AI neural network to identify compounds capable of breaching the protective outer membrane of Mycobacterium tuberculosis, potentially accelerating the search for new TB therapeutics.
-
NewsDual antibody cocktail offers complete Nipah virus protection
Researchers at Mount Sinai have developed the first fully human monoclonal antibody cocktail to provide complete protection against Nipah and Hendra viruses in preclinical models, offering a potential blueprint for treating high-consequence zoonotic pathogens with no approved therapies.
-
NewsEpilepsy drug sodium valproate could improve vaccine immune responses
A commonly prescribed epilepsy drug has shown striking potential as a vaccine booster in a controlled human trial, more than doubling antibody levels and increasing T cell responses tenfold at a fraction of its standard therapeutic dose.
-
NewsStreptomyces antibiotic ‘megacluster’ targets biotin to combat drug-resistant infections
Researchers at McMaster University have identified an unprecedented antibiotic ‘megacluster’ in Streptomyces bacteria, harbouring four co-located gene clusters that produce compounds collectively targeting bacterial biotin biosynthesis, uptake and utilisation — with two proving effective against multidrug-resistant E. coli in animal models.
-
NewsAI uncovers antimicrobial peptides hidden within prion proteins
Researchers at the University of Pennsylvania have used artificial intelligence to identify a new class of antimicrobial peptides within prion proteins, traditionally associated with neurodegenerative disease. The discovery reveals 1,179 potential antibiotic candidates, with laboratory and animal studies confirming activity against drug-resistant bacterial strains.
-
NewsCerebral organoids identify Ebola virus persistence in neural tissue
Researchers have used human brain organoids to demonstrate that Ebola virus can replicate in neural tissue for up to 120 days, offering new insights into viral persistence mechanisms in immune-privileged sites and late-stage inflammatory complications in survivors.
-
ArticleCerebral organoids reveal how Ebola virus persists in neural tissue
How does Ebola virus survive long after recovery? A new study using human cerebral organoids explores viral persistence in neural tissue and the growing role of organoid models in drug discovery research.
-
NewsAI identifies 23 antiviral candidates for Bundibugyo Ebola strain
US researchers have deployed artificial intelligence and molecular docking software to identify 23 antiviral compounds with potential activity against Bundibugyo Ebolavirus, as the rare strain continues to spread in the Democratic Republic of Congo with a fatality rate approaching 40 percent.
-
ArticleWhen antibiotics are not enough: the case for immune-engaging therapies
As antimicrobial resistance grows and patient populations become more complex, the limitations of antibiotics are becoming harder to ignore. Dr Helen Bright, CSO at Centauri Therapeutics, discusses a new approach that targets both the pathogen and the host.
-
NewsMitochondrial fission activation offers new tool in fight against antibiotic resistance
Scientists at The University of Queensland have discovered that activating mitochondrial fission can enhance immune defences against antibiotic-resistant bacteria.
-
NewsCD4+ T cells identified as key to hepatitis B clearance
University of California, San Francisco researchers have identified a crucial immune mechanism involving CD4+ T cells that explains why some chronic hepatitis B patients successfully clear the virus after stopping antiviral treatment.
-
NewsAI system transforms weak antibiotics into powerful treatments
University of Pennsylvania researchers have developed ApexGO, an AI system that refines imperfect antibiotic candidates through calculated modifications rather than database screening.
-
NewsNew malaria drug T111 targets all parasite stages in single treatment
A novel compound developed over 15 years of research has demonstrated unprecedented activity against liver, blood and sexual stages of Plasmodium parasites, possibly positioning it as a potential cure for malaria.
-
NewsTwo antimicrobials show efficacy against drug-resistant pneumonia pathogen
A preclinical study from Osaka Metropolitan University demonstrates that levofloxacin and cefiderocol both show therapeutic potential against severe hemorrhagic pneumonia caused by the multidrug-resistant pathogen Stenotrophomonas maltophilia.
-
NewsNovel enzyme inhibitors exploits key weakness in malaria parasite
Researchers from the Universities of Bath and Leeds have engineered a novel class of aminopeptidase P inhibitors with enhanced binding affinity and antiparasitic activity against Plasmodium falciparum.
-
NewsNew strategy targets antibiotic resistance in cystic fibrosis
Researchers at the University of Texas at Austin have demonstrated that targeting a bacterial protein-folding pathway can disable antimicrobial resistance and cross-protection, restoring antibiotic susceptibility in preclinical models of cystic fibrosis infection.
-
NewsHuman antimicrobial peptide dermcidin shows antiviral activity against influenza
Researchers at Fisabio Foundation have discovered that dermcidin, an antimicrobial peptide naturally present in human sweat, exhibits antiviral activity against influenza by binding to viral haemagglutinin and preventing cell fusion, opening new possibilities for innate immunity-based therapeutics.
-
NewsCC023 mice reveal how ALS can develop after viral infections
Researchers have discovered a mouse strain that mirrors ALS in humans following a viral infection, offering new insights into how the disease develops, potentially opening new pathways for early diagnosis and drug development.
-
NewsELRIG announces keynote speakers for Cell and Gene Therapy 2026 in Cambridge
ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for its inaugural Cell and Gene Therapy 2026 conference, taking place at Hinxton Hall in Cambridge from 9–10 March.